Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03910114 · ClinicalTrials.gov registry record
Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 500
- Enrollment target
NCT03910114 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 500 participants.
The verdict
NCT03910114 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
Rationale: Dotarem provides superior enhancement characteristics compared to other GBCA in fMRU Specific Aims: Compare enhancement characteristics of Dotarem to other GBCAs in the kidneys used in fMRU Primary Objectives: Review functional analysis curves and data of fMRU studies and determine enhancement characteristics in the kidneys of the three GBCAs (Dotarem, Gadovist, Magnevist)
Interventions
- DRUG Dotarem
- DRUG Magnevist
- DRUG Gadovist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 1990-07-01 |
| Est. Completion | 2019-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03910114
The ClinicalTrials.gov registry entry for NCT03910114 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dotarem is the first listed.
NCT03910114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03910114 about?
NCT03910114 is a clinical study titled "Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography". Rationale: Dotarem provides superior enhancement characteristics compared to other GBCA in fMRU Specific Aims: Compare enhancement characteristics of Dotarem to other GBCAs in the kidneys used in fMRU Primary Objectives: Review functional analysis curves and data of fMRU studies and determine enha...
What is the current status of trial NCT03910114?
This trial is currently completed. The enrollment target is 500 participants. The study started on 1990-07-01. Estimated completion is 2019-04-01.
What interventions are being tested in trial NCT03910114?
The interventions under investigation include: Dotarem (DRUG), Magnevist (DRUG), Gadovist (DRUG).
Who is sponsoring clinical trial NCT03910114?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.